Journal: bioRxiv

Article Title: A novel fracture lattice in spiny mouse skin facilitates tissue autotomy and regeneration

doi: 10.64898/2026.03.23.713756

Figure Lengend Snippet: The regional specificity and temporal development of the fracture lattice in Acomys skin. a , H&E images of horizontal sections of head, neck, abdominal, vibrissa, instep, and footpad skin of Acomys . Scale bars, 200 μm. Note that except for a faint pattern in the abdominal skin, the fracture lattice is absent in other skin regions. b , H&E images of horizontal sections of Acomys back skin at different developmental stages. Note that at postnatal day 21, the pattern looks weak and primitive, but at postnatal day 77, the patterns become clear and definitive. Scale bars, 1 mm. c , Schematic depicting the hair cycle of Acomys . d , H&E images of vertical sections of Acomys back skin show the maturation process of the fracture lattice along with the entry of hair cycle of spiny hairs. Scale bars, 1 mm. e , H&E images of horizontal sections of Acomys back skin showing that overexpression of DKK1 disrupted the fracture lattice formation. Scale bars, 1 mm. f , H&E images of horizontal sections of Acomys back skin showing that 5-FU treatment resulted in abnormal formation of the fracture lattice. Scale bars, 1 mm. g , Normalized force-displacement curves of 5-FU treated and control Acomys skin.

Article Snippet: A 5% 5-FU (MedChemExpress) stock solution was prepared by dissolving the compound in DMSO (Sigma-Aldrich).

Techniques: Over Expression, Control

Journal: bioRxiv

Article Title: A novel fracture lattice in spiny mouse skin facilitates tissue autotomy and regeneration

doi: 10.64898/2026.03.23.713756

Figure Lengend Snippet: Genetic and pharmacologic manipulations for inhibiting spiny hair formation. a , H&E images of horizontal sections of Acomys back skin at different developmental stages. Note that during early development, the fracture lattice is absent. Scale bars, 1 mm. b , Schematic illustrations depicting the remodeling process of the fracture lattice from a primitive pattern (P21) to a definitive pattern (P77). c , Schematic depicting the design of lentiviral construct for overexpression Acomys Dkk1 gene. Acomys DKK1 expression and secretion were confirmed by Western blot analysis using an anti-Myc-tag antibody. d , (left) Representative photo of ultrasound-guided lentivirus injection into the yolk sac cavity of an E16.5 Acomys embryo. (right) Fluorescence stereoscope image showing strong expression of H2B-RFP in an E30.5 Acomys embryo. e , Representative images showing that overexpression of AcoDKK1 effectively blocked the formation of hair follicles in Acomys skin. Scale bars, 200μm. f , Experimental timeline of AcoDKK1 overexpression and analysis of fracture lattice formation. g , Experimental timeline of 5-FU treatment and analysis of fracture lattice formation. h , Photographs showing that topical 5-FU treatment effectively inhibited spiny hair formation in Acomys back skin.

Article Snippet: A 5% 5-FU (MedChemExpress) stock solution was prepared by dissolving the compound in DMSO (Sigma-Aldrich).

Techniques: Construct, Over Expression, Expressing, Western Blot, Injection, Fluorescence

Journal: Experimental Hematology & Oncology

Article Title: Tetrahydromagnolol targets TRIM38 to mediate PANoptosis in cancer cells and has the potential for synergistic cancer therapy

doi: 10.1186/s40164-025-00734-4

Figure Lengend Snippet: THM combined with clinical medications exhibited significant synergistic antitumor effect in colorectal cancer animal models. A HCT116 tumor-bearing athymic nude mice tumor inoculation [subcutaneous (s.c.)] and treatment plan. Nine days after tumor inoculation, mice were treated intraperitoneally with THM medium dose, Cetuximab, FOLFOX regimen (5-FU + Calcium levofolinate + Oxaliplatin), FOLFIRI regimen (5-FU + Calcium levofolinate + Irinotecan), THM + Cetuximab, THM + FOLFOX, and THM + FOLFIRI. The THM mid-dose group received 60 mg/kg every other day and the Cetuximab group received 1 mg/mouse daily. FOLFOX group received 5-FU (22.5 mg/kg) and Calcium levofolinate (33.75 mg/kg) on days 1 and 8 and Oxaliplatin (9.375 mg/kg) on days 2 and 9. FOLFIRI received 5-FU (22.5 mg/kg) and Calcium levofolinate (33.75 mg/kg) on days 1 and 8 and Iirinotecan (15 mg/kg) on days 2 and 9. B Photographs of the excised tumors from HCT116 xenograft bearing mice across different treatment groups were captured on day 20 ( n = 5). C-D The average tumor growth curves of all treatment groups. Data was shown as mean ± SD ( n = 5), and significance was determined using two-way ANOVA with Tukey’s multiple comparisons test (*** p < 0.001 and **** p < 0.0001). E Average body weight of HCT116 tumor-bearing mice during the treatment. Data was shown as mean ± SD ( n = 5). F-H Schematic diagrams for calculating the combination index (CI) after treatment with THM in combination with Cetuximab (F), the FOLFOX regimen (G), and the FOLFIRI regimen (H). Data was shown as mean ± SD ( n = 5), * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001 by one-way ANOVA with Tukey’s multiple comparisons test. I Immunohistochemical staining of PANoptosis indexes by subcutaneous tumor-bearing HCT116 colorectal cancer tumor tissue sections combined with clinical drugs (Cetuximab, FOLFOX and FOLFIRI regimens)

Article Snippet: 5-Fluorouracil (5-FU) (HY-9006), Irinotecan (HY-16562), Calcium levofolinate (HY-13667), Oxaliplatin (HY-17371), Necrostatin-1 (Nec-1) (HY-15760), Z-VAD-FMK (HY-16658B), Ferrostatin-1 (Fer-1) (HY-100579), Chloroquine (CQ) (HY-175889A) were acquired from MCE (Monmouth Junction, NJ, USA).

Techniques: Medications, Immunohistochemical staining, Staining